//
Loading stock details...
Healthcare
Bristol-Myers Squibb stock analysis and opportunity scoring
$61.39
As of Oct 29
↑ +1.35%
Bristol-Myers Squibb (BMY) is a publicly traded company in the Healthcare - Drug Manufacturers - General sector tracked by MKD Intelligence.
BMY last traded at $61.39 up 1.35% on the session as of 2026-10-29.
MKD Intelligence assigns BMY a composite opportunity score of 65 out of 100, indicating favourable conditions across trend, momentum and volume factors.
The risk score for BMY is 42 out of 100 (moderate), where a higher number means greater expected volatility.
BMY has a composite opportunity score of 65/100, above the 63.1/100 average across 84 tracked Healthcare stocks. TNDM leads the sector at 79/100.
High
$63.88
Low
$56.67
Period
Oct 29 - Sep 25 (25d)
Hover for details • Scroll to zoom • Drag to pan • Double-click to reset
Patient dies in Bristol Myers Squibb autoimmune CAR-T trial - STAT
STAT · Oct 23
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial - Endpoints News
Endpoints News · Oct 23
Bristol Reverses Despite Double Win. But Its Key Rival Crashed. - Investor's Business Daily
Investor's Business Daily · Oct 12
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth - Fierce Biotech
Fierce Biotech · Oct 12
Data as of Oct 31
This platform provides market intelligence and educational information only. It does not constitute financial advice, and no information presented should be interpreted as a recommendation to buy, sell, or hold any security. Past performance and historical patterns do not guarantee future results.